{"product_id":"tirzepatide-15mg-30mg-research-peptide","title":"Tirzepatide 15mg\/30mg Research Peptide","description":"\u003cp\u003e \u003c\/p\u003e\n\u003ch2 class=\"mb-4 font-heading text-xl font-bold text-white\"\u003eProduct Details\u003c\/h2\u003e\n\u003cdiv class=\"prose-shopify max-w-none\"\u003e\n\u003cp\u003e\u003cstrong\u003eFor Research Purposes Only.\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eNot approved for human consumption.\u003c\/p\u003e\n\u003ch2\u003eTirzepatide Research Peptide\u003c\/h2\u003e\n\u003cp\u003eTirzepatide is a synthetic dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly — the first-in-class twincretin peptide. In Phase 3 SURPASS trials, Tirzepatide achieved up to 22.5% weight loss, surpassing Semaglutide's results and establishing dual agonism as superior to single GLP-1 activation for metabolic endpoints. It serves as a critical comparator in research between single-mechanism (Semaglutide) and triple-mechanism (Retatrutide) approaches.\u003c\/p\u003e\n\u003ch2\u003eResearch Applications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eDual incretin (GIP + GLP-1) receptor research\u003c\/li\u003e\n\u003cli\u003eAdvanced metabolic and obesity biology\u003c\/li\u003e\n\u003cli\u003eComparative single vs. dual agonist efficacy studies\u003c\/li\u003e\n\u003cli\u003eInsulin secretion and glucose metabolism research\u003c\/li\u003e\n\u003cli\u003eBridge research between Semaglutide and Retatrutide mechanisms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eQuality Specifications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePurity: ≥98% (HPLC verified)\u003c\/li\u003e\n\u003cli\u003eCompound: Tirzepatide\u003c\/li\u003e\n\u003cli\u003eMolecular Weight: 4813.5 Da\u003c\/li\u003e\n\u003cli\u003eForm: Lyophilized powder\u003c\/li\u003e\n\u003cli\u003eStorage: -20°C, protect from light\u003c\/li\u003e\n\u003cli\u003eCOA: Batch-specific, ISO-accredited laboratory\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eQ: What makes Tirzepatide unique?\u003c\/strong\u003e\u003cbr\u003eA: First dual GIP\/GLP-1 agonist ('twincretin') to reach Phase 3. Most metabolic peptides target one receptor. Tirzepatide targets two — establishing dual agonism as superior to single-mechanism approaches.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: What were the SURPASS trial results?\u003c\/strong\u003e\u003cbr\u003eA: Tirzepatide achieved up to 22.5% weight loss in Phase 3 trials — exceeding Semaglutide's ~15% and setting the stage for triple agonists like Retatrutide to push further.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ: How does Tirzepatide fit between Semaglutide and Retatrutide?\u003c\/strong\u003e\u003cbr\u003eA: It is the middle tier: Semaglutide = single agonist (GLP-1 only); Tirzepatide = dual agonist (GLP-1 + GIP); Retatrutide = triple agonist (GLP-1 + GIP + Glucagon). Research often compares all three.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cp\u003e   \u003c\/p\u003e","brand":"Simple Research Peptides","offers":[{"title":"Tirzepatide 30mg Research Peptide","offer_id":45803997986850,"sku":null,"price":200.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0878\/4478\/2114\/files\/tirzepatide-15mg30mg-research-peptide-3432940.png?v=1782099787","url":"https:\/\/simpleresearchpeptides.com\/products\/tirzepatide-15mg-30mg-research-peptide","provider":"Simple Research Peptides","version":"1.0","type":"link"}